MPTP


Also found in: Acronyms, Wikipedia.

MPTP

Piperidine derivative that causes irreversible symptoms of parkinsonism in humans and monkeys. A by-product of illicitly manufactured meperidine that caused numerous cases of parkinsonism. Used as an experimental tool in research on parkinsonism.

MPTP

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, analogs MTMP, PEPAP Neurology A potent neurotoxin–which has an effect much like Meperidine or Demerol—that acts on neuromelanin, producing parkinsonism Clinical Bradykinesia, muscular rigidity, resting tremor, defects of posture and gait Pharmacologic effects MPTP initially blocks the brain's responses to pain, then metabolizes to MPP+, causing an irreversible syndrome resembling Parkinson's disease. See BDNF, Designer drugs, Parkinson's disease.
References in periodicals archive ?
The MPTP includes forming a comprehensive metro and bus network, as well as substantial upgrades and new construction for the primary road network.
The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model.
Numerous studies show that opening of the MPTP is associated with common diseases of aging, and with markers of aging itself in human tissues.
Inhibidores de la desacetilacion de la histona 3 producen un efecto neuroprotector en celulas dopaminergicas ante la administracion de 6OHDA y MPTP (Zhou et al.
Surprisingly, subsequent studies suggested that mitochondria could play a pivotal role in ischemia/reperfusion injury by opening the MPTP.
The study comprises 18 primates, all exposed to the neurotoxin MPTP, divided into three cohorts, a sham treated group and two treatment groups receiving different doses of human neural stem cells (hPNSC) derived from ISCO's proprietary parthenogenetic stem cell line.
The opening of the MPTP leads to mitochondrial dysfunction.
76,77 Mice treated with Methyl-phenyl-tetrahydropyridine (MPTP) are used as an animal model of Parkinson\'s disease because MPTP administration results in neuronal damage in the nigrostriatal pathway.
Mice deficient in dihydrolipoamide dehydrogenase show increased vulnerability to MPTP, malonate and 3-nitropropionic acid neurotoxicity.
MPTP causes damage to brain cells that respond to the neurotransmitter dopamine, leading to problems in muscle control, including tremors and difficulty walking.
When the mitochondrial membrane potential is disturbed by a large calcium uptake or other triggers such as physiological stress, the mitochondrial permeability transition pore/ MPTP opens up and releases Cyt C.